In a comparable PTC cohort from The Cancer Genome Atlas study, the prevalence of RAS variants was 12.9% in PTCs, including 8.5% with NRAS, 3.5% with HRAS, and 1.0% with KRAS, based on NGS assays.11 In contrast, our study observed a prevalence of 23.1% for RAS variants in PTCs, classified by the 2017 WHO classification,29 including 13.5% with NRAS, 7.4% with HRAS, and 2.2% with KRAS (eFigure 3 in Supplement 1), suggesting that VAF assays revealed higher frequencies of RAS variants in thyroid neoplasms. Here, KRAS is linked to thyroid tumor.